← Back to Search

Antiviral

BEM vs BEM + Ruzasvir n=16 for Healthy Volunteer Study (AT-527 Trial)

Phase 1

Waitlist Available

Research Sponsored by Atea Pharmaceuticals, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up days 6, 12, 18

Awards & highlights

AT-527 Trial Summary

This trial tested how two drugs, Ruzasvir & Bemnifosbuvir, interact when taken together to treat Hepatitis C.

AT-527 Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ days 6, 12, 18

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~days 6, 12, 18

This trial's timeline: 3 weeks for screening, Varies for treatment, and days 6, 12, 18 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Pharmacokinetics (PK) of BEM

Pharmacokinetics (PK) of Ruzasvir

AT-527 Trial Design

2Treatment groups

Experimental Treatment

Group I: Ruzasvir vs Ruzasvir + BEM n=16Experimental Treatment1 Intervention

Group II: BEM vs BEM + Ruzasvir n=16Experimental Treatment1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Cohort 1 BEM + Ruzasvir

2023

Completed Phase 1

~40

Cohort 2 Ruzasvir + BEM

2023

Completed Phase 1

~40

Do I qualify?Apply below to find out

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Atea Pharmaceuticals, Inc.Lead Sponsor

27 Previous Clinical Trials

4,000 Total Patients Enrolled

12 Trials studying Healthy Volunteer Study

441 Patients Enrolled for Healthy Volunteer Study

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research accommodating individuals over 45 years of age?

"Individuals aged between 18 and 55 can join this clinical trial."

Answered by AI

What are the relative safety implications of BEM alone versus a combination treatment with BEM and Ruzasvir among 16 patients?

"The safety of BEM combined with Ruzasvir, based on the small sample size of 16 patients, has been deemed a 1 due to its Phase 1 clinical trial status. This implies that there is only limited data available supporting both safety and efficacy."

Answered by AI

Is this trial currently open for enrollment?

"Affirmative. According to clinicaltrials.gov, this medical trial is presently searching for volunteers and was first posted on January 30th 2023 with the latest update occurring on February 9th of that same year. 32 individuals are required from 1 trial site in total."

Answered by AI

How many participants are actively involved in this clinical investigation?

"Affirmative. Clinicaltrials.gov records point to this medical study still recruiting patients, which was initially posted on January 30th 2023 and last updated February 9th of the same year. There are 32 positions available at a single site for prospective participants."

Answered by AI

Are there any particular demographics that would make someone a favorable candidate for this clinical trial?

"This clinical trial requires 32 volunteers aged 18-55 with a healthy body weight of 50 kilograms and BMI between 18-29 kg/m2. In addition, participants must agree to use two forms of contraception from Screening through 90 days after taking the last dose of medication. Furthermore, all candidates must be willing to comply with the study's requirements and provide written informed consent."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Drug-drug Interaction Study of Ruzasvir and Bemnifosbuvir

2023. "Drug-drug Interaction Study of Ruzasvir and Bemnifosbuvir". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05731843.